Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: Valeant Pharmaceuticals International, Inc. vs. Gilead Sciences


Better Buy: Valeant Pharmaceuticals International, Inc. vs. Gilead Sciences

When it comes to the high-flying healthcare sector, there aren't many bargains to be had. President Trump's recent change of heart regarding the possibility of hard caps on high-priced prescription drugs, after all, sparked a widespread rally that's caused valuations to balloon over the past month or so. 

Valeant Pharmaceuticals International (NYSE: VRX) and Gilead Sciences (NASDAQ: GILD), however, are two high-profile names that are still arguably "cheap" -- at least based on their rock-bottom price-to-sales ratios of 0.63 and 3.22, respectively. Armed with this insight, let's consider which of these two bargain-bin healthcare stocks is the better buy right now. 

Image Source: Getty Images.

Continue reading


Source: Fool.com

Bausch Health Companies Inc. Stock

€5.30
-1.010%
A loss of -1.010% shows a downward development for Bausch Health Companies Inc..
Bausch Health Companies Inc. is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
With a target price of 12 € there is potential for a 126.24% increase which would mean more than doubling the current price of 5.3 € for Bausch Health Companies Inc..
Like: 0
VRX
Share

Comments